Evidence Hub

Systemic Mastocytosis Successfully Managed using Cytosorb ® During Cardiopulmonary Bypass for Aortic Valve Replacement

Gross A, Colombier S, Arlettaz L, Delay D

Annals of cardiac anaesthesia, 2024

Abstract

Abstract: We describe the case of a 72-year-old male with a history of systemic mastocytosis scheduled for on-pump aortic valve replacement for severe aortic insufficiency. Anesthesia and peri-operative management included avoidance of histamine-releasing drugs, methylprednisolone and clemastin prophylaxis. Furthermore, a CytoSorb ® cartridge has been added to the bypass circuit and hemoadsorption was performed throughout the entire cardiopulmonary bypass (CPB) duration. CytoSorb ® is a hemoadsorption device designed to remove various cytokines and drugs from the blood. The use of CytoSorb ® during CPB in our case was not associated with adverse events, and the patient did not present any allergic or anaphylactic reaction.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free